Overview
- The Pharmacy Compounding Advisory Committee voted July 24 to recommend adding BPC‑157, KPV, TB‑500, MOTS‑c, Epitalon and Semax to the 503A bulk drug substances list and voted against emideltide.
- Those recommendations are non‑binding and the FDA said it will review the meeting record, public comments and staff analyses before deciding whether to publish a proposed rule.
- Career FDA scientists and many outside medical experts urged the panel to keep restrictions, citing weak clinical evidence, uncertain dosing, batch contamination and reports of serious immune and other harms.
- Several new panel members who voted to expand access have disclosed financial ties to peptide clinics, pharmacies or telehealth firms, which has intensified conflict‑of‑interest concerns.
- If the FDA finalizes a change, licensed compounding pharmacies could legally prepare these peptides for patients with prescriptions but the drugs would not become FDA‑approved and any agency action could take months to a year.